
    
      Approximately 120 male or female patients with newly diagnosed or relapsing moderate to
      severe pemphigus (pemphigus vulgaris [PV] or pemphigus foliaceus [PF]) will be enrolled in
      the trial worldwide.

      The trial will last 68 weeks (approximately 17 months) for each participant. For patients
      eligible to enroll in the Long Term Extension, the trial may last up to 116 weeks.

      Patients will be randomized at Day 1, using a 1:1 ratio to receive PRN1008 or placebo twice
      per day, by relapsing/newly diagnosed disease history (newly diagnosed defined as within 6
      months of Screening).
    
  